Strongbridge Reports Results of Post Hoc Analyses from a One Year HYPHOP Study of Keveyis (dichlorphenamide) to Treat Primary Periodic Paralysis

July 14, 2021 Auto Bot Clinical Trials 0

Shots:

  • The open-label, HYPHOP study involves assessing Keveyis vs PBO in patients with PPP, following 9wks. controlled study. The results are published in the journal, Muscle & Nerve
  • The results from post hoc analyses of the HYPHOP study confirmed that the therapy is safe and effective for chronic use, efficacy was maintained @61wks., reduction in attacks rates in patients receiving Keveyis continuously than among those switching from PBO to Keveyis after 9wks.
  • Additionally, AEs analyses indicate no new safety signals in the 52wks. of the study compared to the first 9 wks. while results reinforce the utility of Keveyis as an effective option to treat PPP

Click here to read full press release/ article | Ref: Globe Newswire | Image: Businesswire

The post Strongbridge Reports Results of Post Hoc Analyses from a One Year HYPHOP Study of Keveyis (dichlorphenamide) to Treat Primary Periodic Paralysis first appeared on PharmaShots.